Percepta® is a patent-protected brain health natural dietary supplement (active ingredients, PTI-00703® Cat’s claw and MemorTea® - a specific oolong tea extract). Cerebrum DAO will be supporting the development of near- and long-term solutions for targeting cognitive decline, memory loss and neurodegenerative diseases. The global market for brain health supplements is over $8.6b - most if not all lack clinical evidence to support efficacy. Percepta® has robust patent protection and highly promising research results. Percepta has the potential to be the category leader in this fast growing $8.6b market with human evidence to support outcomes and the funding of future studies that could lead to FDA botanical drug status which is the ultimate goal. This IP-NFT represents a world’s first tokenization of a robust patent portfolio and a world’s first tokenized crowdsale for a clinical evidence study. Success with this study can lead to future trials that create the potential for FDA botanical drug approval, potentially unlocking broad access to improve brain health globally.
Percepta® is a patent-protected brain health natural dietary supplement (active ingredients, PTI-00703® Cat’s claw and MemorTea® - a specific oolong tea extract). Cerebrum DAO will be supporting the development of near- and long-term solutions for targeting cognitive decline, memory loss and neurodegenerative diseases.
The global market for brain health supplements is over $8.6b - most if not all lack clinical evidence to support efficacy. Percepta® has robust patent protection and highly promising research results.
Percepta has the potential to be the category leader in this fast growing $8.6b market with human evidence to support outcomes and the funding of future studies that could lead to FDA botanical drug status which is the ultimate goal.
This IP-NFT represents a world’s first tokenization of a robust patent portfolio and a world’s first tokenized crowdsale for a clinical evidence study.
Success with this study can lead to future trials that create the potential for FDA botanical drug approval, potentially unlocking broad access to improve brain health globally.
Mark Melnykowycz
Research Lead
Time | Type | $CLAW | USD | ETH | From |
|---|---|---|---|---|---|
Therapeutic Relevance
Strong preclinical evidence targeting amyloid/tau pathology in MCI with peer-reviewed validation.
Therapeutic Optionality
Neuroinflammation and oxidative stress mechanisms could extend to broader neurodegeneration.
Intellectual Property
12+ core patents secured under Cognitive Clarity portfolio; robust and defensible IP position.
Utility Of Candidates
69.6% amyloid and 85.7% tau aggregation reduction in vitro; outperformed 20+ competitors.
Prospects For Safety
Botanical ingredients with established dietary use; no preclinical safety concerns identified.
Prospects For Gmp Cmc
Small-scale commercial production already operational; botanical manufacturing is feasible.
Prospects For Clinical Development
IRB-approved RCT with clear endpoints; regulatory pathway noted but IND status uncertain.
Commercial Potential
$8.6B brain supplement market growing at 13.3% CAGR; clear competitor gap in evidence.
Organization And Team Fit
Experienced PI and CRO partnership, but DeSci/DAO structure introduces execution uncertainty.